12-31-2022
| USD/share | |
| Price | 113.80 |
| Dividend | 0.00 |
| Earnings | 3.84 |
| Cash-flow | 4.57 |
| Book value | 20.69 |
| Equity | 19.20 |
Horizon Therapeutics is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. Horizon Therapeutics is a company from USA, and his stocks are publicly traded.
Horizon Therapeutics paid a total dividend of 0 million USD last year, for a market value of 25,833 millions (Market Cap 25,141 millions). Dividend per share of Horizon Therapeutics is 0.00 USD, and his stock market price 113.80 USD.
According to the chart below where dividend yield is displayed, Horizon Therapeutics, has a dividend yield of 0%, amount in contrast with the positive dividend offered by both the market average and companies from USA, Health Care industry, and Pharmaceuticals and Biotechnology sector. This lack of dividends of Horizon Therapeutics might harm the evolution of share price if the company is not clearly expanding his business.
In addition, you should compare Horizon Therapeutics dividend yield with other Pharmaceuticals and Biotechnology companies or firms from USA.
Horizon Therapeutics Dividend Payout
About the ability of Horizon Therapeutics to maintain his current dividend of USD 0.00 per share, an amount that accounts for 0.00%, we should study its payout ratio both on earnings and on cash-flows (see chart below). Horizon Therapeutics payout on ernings is currently 0.00%, which is lower than the market average and companies in his industry and sector.
The following figure shows payout ratios over earnings and cashflow of Horizon Therapeutics, compared againt world market average, USA companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.
Horizon Therapeutics Dividend History
No data available
Horizon Therapeutics Stock performance
Finally, last moth Horizon Therapeutics showed a return of 13.50% compared to a worldwide -2.30% average, and a -1.20% of Health Care firms. Over the last year, the company obtained a 5.60% versus a worldwide performance of a -5.85%. More detailed information can be seen in the following graph for USA and Pharmaceuticals and Biotechnology firms.
